Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis.
[lymphangioleiomyomatosis]
Lymphangioleiomyomatosis
(
LAM
)
is
characterised
by
lung
cysts
and
airflow
obstruction
.
Matrix
metalloproteinases
have
been
implicated
in
lung
destruction
in
LAM
.
We
performed
a
randomised
,
double
-blind
trial
,
comparing
the
matrix
metalloproteinases
inhibitor
doxycycline
with
placebo
on
the
progression
of
LAM
.
23
females
with
LAM
were
randomised
to
doxycycline
100
mg
daily
for
3
months
followed
by
200
mg
daily
for
21
months
,
or
matched
placebo
.
Lung
function
,
exercise
capacity
,
quality
of
life
and
matrix
metalloproteinases
levels
were
measured
.
21
patients
completed
6
months
of
treatment
,
17
completed
1
year
of
treatment
and
15
completed
2
years
of
treatment
.
Eight
withdrew
from
the
trial
due
,
four
due
to
a
pneumothorax
and
four
because
of
other
reasons
.
The
mean
±
sd
decline
in
FEV
1
,
the
primary
endpoint
,
did
not
differ
between
the
groups
being
-
90
±
154
mL
·
year
(
-
1
)
in
the
placebo
group
and
-
123
±
246
mL
·
year
(
-
1
)
in
the
doxycycline
group
(
difference
-
32
.
5
,
95
%
CI
-
213
-
148
;
p
=
0
.
35
)
.
Doxycycline
had
no
effect
upon
vital
capacity
,
gas
transfer
,
shuttle
walk
distance
or
quality
of
life
.
Urine
matrix
metalloproteinases-
9
measurements
were
lower
with
doxycycline
treatment
(
p
=
0
.
03
)
.
Although
with
limited
numbers
we
can
not
completely
exclude
an
effect
of
doxycycline
,
the
lack
of
effect
on
any
outcome
makes
it
unlikely
that
doxycycline
has
a
useful
effect
in
LAM
.
Diseases
Validation
Diseases presenting
"lung function"
symptom
allergic bronchopulmonary aspergillosis
congenital diaphragmatic hernia
lymphangioleiomyomatosis
monosomy 21
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom